PROSTATE SPECIFIC ANTIGEN PROTEOLYTIC ACTIVITY FOR CLINICAL USE

摘要

Methods for predicting the outcome of and monitoring prostate cancer patients using prostate specific antigen (PSA) proteolytic activity (PPA) in combination with other molecular biomarkers or other parameters are described. Methods of determining sets of parameters for use in predicting the outcome of and monitoring of prostate cancer patients are also described.